Results 111 to 120 of about 28,869 (265)

Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system

HIV Medicine, Volume 27, Issue 5, Page 749-760, May 2026.
Abstract Objective Integrase strand transfer inhibitors (INSTIs) are widely used in antiretroviral therapy (ART) for people with HIV due to their efficacy and tolerability. However, concerns about weight gain and metabolic disturbances have emerged.
Leidan Zhang, Ling Chen, Jia Tang, Xiaosheng Liu, Liyuan Zheng, Fada Wang, Xin Huang, Wei Cao, Taisheng Li   +8 more
wiley   +1 more source

Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study

Aids and Behavior
SOLAR (NCT04542070; registered 2020–09-09) is a Phase 3b study that demonstrated the noninferior virological efficacy of switching to cabotegravir + rilpivirine long-acting (CAB + RPV LA) dosed every 2 months vs.
C. Mussini, C. Cazanave, E. Adachi, B. Eu, Marta Montero Alonso, G. Crofoot, Vasiliki Chounta, Irina Kolobova, K. Sutton, Denise Sutherland-Phillips, R. Urbaityte, Alice Ehmann, Jenny Scherzer, Patricia de los Rios, Ronald D'Amico, W. Spreen, J. van Wyk   +16 more
semanticscholar   +1 more source

Highlights from the 9th IAS conference on HIV science, 23-26 July 2017, Paris, France [PDF]

, 2017
The 9th International AIDS Society Conference on HIV Science (IAS 2017) took place at the Palais des Congrès, in Paris, France, from 23 to 26 July 2017, chaired by Linda-Gail Bekker and Jean-François Delfraissy. It was organised by the International AIDS
Barber, Tristan J, Kinloch-de Loës, Sabine, Psomas, Christina K, Rutsaert, Sofie   +3 more
core   +2 more sources

Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy

AIDS (London)
Objective: To evaluate the efficacy and safety of 96 weeks of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) treatment in participants switching from dolutegravir (DTG)-based therapy.
C. Orkin, A. Antinori, Jürgen K. Rockstroh, Santiago Moreno-Guillén, C. Martorell, J. Molina, Adriano Lazzarin, F. Maggiolo, Y. Yazdanpanah, Kristen N. Andreatta, Hailin Huang, J. Hindman, Hal Martin, A. Pozniak   +13 more
semanticscholar   +1 more source

Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy. [PDF]

, 2019
Objective: To describe data with selected malignancies in people living with HIV (PLWH) and HIV in individuals affected by both conditions and to summarize drug-drug interactions (DDIs) with clinical recommendations for point-of-care review of ...
Chan, Alexandre, Klibanov, Olga, Olin, Jacqueline L, Spooner, Linda M   +3 more
core   +1 more source

Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate

AIDS Research and Therapy
Concerns of increased metabolic dysfunction have been heightened for HIV patients on long-term antiretroviral therapy (ART). Among first-line ART agents, Tenofovir alafenamide (TAF) may entail a marked increase in weight compared to Tenofovir disoproxil ...
Hamed Mirmoezzi, Hamid Emadi Koochak, Seyed Ali Dehghan Manshadi, Malihe Hasannezhad, SeyedAhmad SeyedAlinaghi, Kiavash Semnani, Ladan Abbasian, Sara Ghaderkhani   +7 more
doaj   +1 more source

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

Journal of Virus Eradication, 2018
Background: Higher plasma tenofovir concentrations are associated with higher risks of renal and bone adverse events. The pharmacokinetic boosters ritonavir (RTV) and cobicistat (COBI) significantly increase plasma area under the curve (AUC ...
Andrew Hill, Sophie L. Hughes, Dzintars Gotham, Anton L. Pozniak   +3 more
doaj   +1 more source

136 HIV-1 Nef regulates activity of endoplasmic reticulum chaperone calnexin [PDF]

, 2014
HIV-1 Nef promotes viral replication by downmodulating a number of cell surface transmembrane proteins, such as CD4, MHC-I and MHC-II, which are targeted by Nef to various degradation pathways.
Bukrinsky*, Michael, Dubrovsky, Larisa, Fitzgerald, Michael L., Hunegnaw, Ruth, Jennelle, Lucas, Pushkarsky, Tatiana, Sviridov, Dmitri   +6 more
core   +1 more source

Reply to: “Promising Drugs Require Proper Testing”: Let's Not Confuse Pharmacodynamics With Clinical Efficacy

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
Inès Ben Ghezala, Marc Bardou
wiley   +1 more source

Efficacy and safety of tenofovir and entecavir in patients with chronic hepatitis B-related cirrhosis: a systematic review and meta-analysis

Frontiers in Pharmacology
ObjectivesTo systematically evaluate the efficacy and safety of tenofovir and entecavir in chronic hepatitis B-related cirrhosis.MethodsA comprehensive search was conducted in databases including PubMed, Web of Science, Embase and Cochrane Library from ...
Lu Cao, Li Li, Lixing Yang, Nan Zhou, Yu Zhang   +4 more
doaj   +1 more source